Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)

Authors: Gogas, Helen, Dummer, Reinhard, Ascierto, Paolo A., Arance, Ana, Mandalà, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsová, Ivana, Gutzmer, Ralf, Sileni, Vanna Chiarion, Dutriaux, Caroline, Yamazaki, Naoya, Loquai, Carmen, Queirolo, Paola, Jan de Willem, Groot, Sellier, Abir Tadmouri, Suissa, Jeanne, Murris, Juliette, Gollerkeri, Ashwin, Robert, Caroline, Flaherty, Keith T.

Source: In European Journal of Cancer July 2021 152:116-128

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

Authors: Ascierto, Paolo A., Dummer, Reinhard, Gogas, Helen J., Flaherty, Keith T., Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, de Groot, Jan Willem B., Loquai, Carmen, Gollerkeri, Ashwin, Pickard, Michael D., Robert, Caroline

Source: In European Journal of Cancer February 2020 126:33-44

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

Authors: Gogas, Helen J., Flaherty, Keith T., Dummer, Reinhard, Ascierto, Paolo A., Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Sileni, Vanna Chiarion, Dutriaux, Caroline, de Groot, Jan Willem B., Yamazaki, Naoya, Loquai, Carmen, Gollerkeri, Ashwin, Pickard, Michael D., Robert, Caroline

Source: In European Journal of Cancer September 2019 119:97-106

A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer

Authors: del Campo, Josep María, Birrer, Michael, Davis, Craig, Fujiwara, Keiichi, Gollerkeri, Ashwin, Gore, Martin, Houk, Brett, Lau, Susie, Poveda, Andres, González-Martín, Antonio, Muller, Carolyn, Muro, Kei, Pierce, Kristen, Suzuki, Mie, Vermette, Jennifer, Oza, Amit

Source: In Gynecologic Oncology July 2016 142(1):62-69

Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]

Authors: Gogas, Helen, Dummer, Reinhard, Ascierto, Paolo A., Arance, Ana, Mandalà, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsová, Ivana, Gutzmer, Ralf, Chiarion Sileni, Vanna, Dutriaux, Caroline, Yamazaki, Naoya, Loquai, Carmen, Queirolo, Paola, de Willem, Groot J., Sellier, Abir T., Suissa, Jeanne, Murris, Juliette, Gollerkeri, Ashwin, Robert, Caroline, Flaherty, Keith T.

Source: European journal of cancer. 160:287-288

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100151124036.0x000001&indx=1&recIds=ETOCvdc_100151124036.0x000001

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).

Authors: Kopetz, Scott, Grothey, Axel, Yaeger, Rona, Ciardiello, Fortunato, Desai, Jayesh, Kim, Tae Won, Maughan, Tim, Van Cutsem, Eric, Wasan, Harpreet Singh, Yoshino, Takayuki, Edwards, Michelle L., Golden, Adele, Gollerkeri, Ashwin, Tabernero, Josep

Source: Journal of clinical oncology. 40(4 suppl):TPS211-TPS211

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152958639.0x000001&indx=1&recIds=ETOCvdc_100152958639.0x000001

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Authors: Shastri, Aditi, Feldman, Eric J, Starodub, Alexander N, Feldman, Tatyana, Rodriguez, Cristina P, Epstein-Peterson, Zachary D., Stevens, Don A., Olszewski, Adam J, Huen, Auris O, Porcu, Pierluigi, Reneau, John C, Barta, Stefan K., Marchi, Enrica, Mattour, Ahmad H, Pinter-Brown, Lauren C., Perea, Rachelle, Donohue, Sean, Dey, Joyoti, Agarwal, Sagar, Karnik, Rahul, Gollerkeri, Ashwin, Gollob, Jared, Smith, Stephen D

Source: In Blood 2 November 2023 142 Supplement 1:3081-3081

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

Authors: Ottmann, Oliver ^*, Dombret, Hervé, Martinelli, Giovanni, Simonsson, Bengt, Guilhot, Francois, Larson, Richard A., Rege-Cambrin, Giovanna, Radich, Jerald, Hochhaus, Andreas, Apanovitch, Anne Marie, Gollerkeri, Ashwin, Coutre, Steven

Source: In Blood 1 October 2007 110(7):2309-2315

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

Authors: Guilhot, Francois ^*, Apperley, Jane, Kim, Dong-Wook, Bullorsky, Eduardo O., Baccarani, Michele, Roboz, Gail J., Amadori, Sergio, de Souza, Carmino A., Lipton, Jeffrey H., Hochhaus, Andreas, Heim, Dominik, Larson, Richard A., Branford, Susan, Muller, Martin C., Agarwal, Prasheen, Gollerkeri, Ashwin, Talpaz, Moshe

Source: In Blood 15 May 2007 109(10):4143-4150

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

Authors: Cortes, Jorge ^*, Rousselot, Philippe, Kim, Dong-Wook, Ritchie, Ellen, Hamerschlak, Nelson, Coutre, Steven, Hochhaus, Andreas, Guilhot, Francois, Saglio, Giuseppe, Apperley, Jane, Ottmann, Oliver, Shah, Neil, Erben, Philipp, Branford, Susan, Agarwal, Prasheen, Gollerkeri, Ashwin, Baccarani, Michele

Source: In Blood 15 April 2007 109(8):3207-3213

IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial

Authors: Ackerman, Lindsay, Acloque, Gerard, Bacchelli, Sandro, Schwartz, Howard, Feinstein, Brian J., La Stella, Phillip, Alavi, Afsaneh, Gollerkeri, Ashwin, Davis, Jeffrey, Campbell, Veronica, McDonald, Alice, Agarwal, Sagar, Karnik, Rahul, Shi, Kelvin, Mishkin, Aimee, Culbertson, Jennifer, Klaus, Christine, Enerson, Bradley, Massa, Virginia, Kuhn, Eric, Sharma, Kirti, Keaney, Erin, Barnes, Randy, Chen, Dapeng, Zheng, Xiaozhang, Rong, Haojing, Sabesan, Vijay, Ho, Chris, Mainolfi, Nello, Slavin, Anthony, Gollob, Jared A.

Source: Nature Medicine; 20230101, Issue: Preprints p1-10, 10p

Global BRAF testing practices in metastatic colorectal cancer (mCRC).

Authors: Desai, Jayesh, Kopetz, Scott, Grothey, Axel, Ciardiello, Fortunato, Kim, Tae Won, Maughan, Tim, Van Cutsem, Eric, Wasan, Harpreet Singh, Yaeger, Rona, Yoshino, Takayuki, Gollerkeri, Ashwin, Edwards, Michelle L., Rodriguez Lizaso, Montessa, Tabernero, Josep

Source: Journal of clinical oncology. 39(15 suppl):e15523-e15523

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173193861.0x000001&indx=1&recIds=ETOCvdc_100173193861.0x000001

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).

Authors: Kopetz, Scott, Grothey, Axel, Yaeger, Rona, Ciardiello, Fortunato, Desai, Jayesh, Kim, Tae Won, Maughan, Tim, Van Cutsem, Eric, Wasan, Harpreet Singh, Yoshino, Takayuki, Edwards, Michelle L., Golden, Adele, Gollerkeri, Ashwin, Tabernero, Josep

Source: Journal of clinical oncology. 39(15 suppl):TPS3619-TPS3619

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173193590.0x000001&indx=1&recIds=ETOCvdc_100173193590.0x000001

Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC).

Authors: Kopetz, Scott, Aderka, Dan, Grothey, Axel, Van Cutsem, Eric, Yaeger, Rona, Wasan, Harpreet Singh, Yoshino, Takayuki, Desai, Jayesh, Ciardiello, Fortunato, Gollerkeri, Ashwin, Golden, Adele, Edwards, Michelle L., Tabernero, Josep

Source: Journal of clinical oncology. 39(15 suppl):3583-3583

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173193222.0x000001&indx=1&recIds=ETOCvdc_100173193222.0x000001

Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study.

Authors: Kopetz, Scott, Murphy, Danielle A., Pu, Jie, Ciardiello, Fortunato, Desai, Jayesh, Grothey, Axel, Van Cutsem, Eric, Wasan, Harpreet Singh, Yaeger, Rona, Yoshino, Takayuki, Donahue, Amber C, Golden, Adele, Gollerkeri, Ashwin, Zhu, Zhou, Tabernero, Josep

Source: Journal of clinical oncology. 39(15 suppl):3513-3513

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173192203.0x000001&indx=1&recIds=ETOCvdc_100173192203.0x000001

Resistance to Inhibitor Compounds of Thymidylate Synthase

Authors: Chu, Edward, Gollerkeri, Ashwin

Source: Encyclopedia of Cancer. 2002, v. 4, p107-113.

Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader

Authors: Ivanova, Ellie ^*, Tegla, Cosmin A, Novikova, Ekaterina ^*, Herrera, Alberto M ^*, Mullins, Briana ^*, Latkowski, Jo-Ann ^*, Hymes, Kenneth B., Dey, Joyoti ^*, Yang, Bin ^*, Gollerkeri, Ashwin ^*, Gollob, Jared ^*, Koralov, Sergei B. ^*

Source: In Blood 15 November 2022 140 Supplement 1:3557-3558

A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers

Authors: Liu, Phillip CC, Dixit, Vaishali, Mayo, Michele, Dey, Joyoti, Yuan, Karen, Karnik, Rahul, Walther, Dirk, Shi, Yatao, Sharma, Kirti, Rong, Haojing, Yang, Bin, Gollerkeri, Ashwin, Gollob, Jared, DeSavi, Chris

Source: In Blood 23 November 2021 138 Supplement 1:1865-1865

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.

Authors: Tabernero, Josep, Grothey, Axel, Van Cutsem, Eric, Yaeger, Rona, Wasan, Harpreet, Yoshino, Takayuki, Desai, Jayesh, Ciardiello, Fortunato, Loupakis, Fotios, Hong, Yong Sang, Steeghs, Neeltje, Guren, Tormod Kyrre, Arkenau, Hendrik-Tobias, Garcia-Alfonso, Pilar, Elez, Elena, Gollerkeri, Ashwin, Maharry, Kati, Christy-Bittel, Janna, Kopetz, Scott

Source: Journal of Clinical Oncology; 2/1/2021, Vol. 39 Issue 4, p273-284, 12p

P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT‐253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS.

Authors: Schalm, Stefanie, Chutake, Yogesh, Breitkopf, Susanne, Mayo, Michele, Dumont, Nancy, Chen, Dapeng, Dixit, Vaishali, Karnik, Rahul, Mcdonald, Alice, Filiatrault, Jessica, Proctor, William, Qi, Frank, Hu, Kan‐Nian, Weiss, Matt, Gollerkeri, Ashwin, Sharma, Kirti, D Growney, Joseph, Williams, Juliet

Source: HemaSphere; 2023 Supplement 3, Vol. 7, p1-2, 2p